1
|
Cait A, Woods K, Naidoo K, Gell K, Schmidt A, Jackson R, Grooby A, O'Sullivan D, Gasser O. Tissue-specific contribution of mucosal-associated invariant T cells to allergic airway inflammation. Allergy 2024; 79:1962-1965. [PMID: 38269416 DOI: 10.1111/all.16038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 12/19/2023] [Accepted: 01/14/2024] [Indexed: 01/26/2024]
Affiliation(s)
- Alissa Cait
- Malaghan Institute of Medical Research, Wellington, New Zealand
- High-Value Nutrition National Science Challenge, Auckland, New Zealand
| | - Katherine Woods
- Malaghan Institute of Medical Research, Wellington, New Zealand
| | - Karmella Naidoo
- Malaghan Institute of Medical Research, Wellington, New Zealand
| | - Katie Gell
- Malaghan Institute of Medical Research, Wellington, New Zealand
- High-Value Nutrition National Science Challenge, Auckland, New Zealand
| | - Alfonso Schmidt
- Malaghan Institute of Medical Research, Wellington, New Zealand
| | | | - Alix Grooby
- Malaghan Institute of Medical Research, Wellington, New Zealand
| | - David O'Sullivan
- Malaghan Institute of Medical Research, Wellington, New Zealand
- High-Value Nutrition National Science Challenge, Auckland, New Zealand
| | - Olivier Gasser
- Malaghan Institute of Medical Research, Wellington, New Zealand
- High-Value Nutrition National Science Challenge, Auckland, New Zealand
| |
Collapse
|
2
|
Bui DV, Nguyen LM, Kanda A, Chu HH, Thi Le NK, Yun Y, Kobayashi Y, Suzuki K, Mitani A, Shimamura A, Fukui K, Sawada S, Dombrowicz D, Iwai H. CD69 Signaling in Eosinophils Induces IL-10 Production and Apoptosis via the Erk1/2 and JNK Pathways, Respectively. Biomolecules 2024; 14:360. [PMID: 38540778 PMCID: PMC10968075 DOI: 10.3390/biom14030360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Revised: 03/11/2024] [Accepted: 03/13/2024] [Indexed: 04/04/2024] Open
Abstract
INTRODUCTION Eosinophils contribute to the pathogenesis of allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis. We previously reported that human tissue eosinophils have high CD69 expression compared to blood eosinophils, and its expression is correlated with disease severity and the number of infiltrated eosinophils. However, biological CD69 signaling activity in eosinophils remains unclear. METHODS CD69 expression on lung tissue eosinophils obtained from mice with ovalbumin-induced asthma was measured using flow cytometry. CD69 crosslinking was performed on eosinophils purified from the spleen of IL-5 transgenic mice to investigate CD69 signaling and its function in eosinophils. Then, qPCR, Western blot, enzyme-linked immunosorbent assay, and survival assay results were analyzed. RESULTS Surface CD69 expression on lung tissue eosinophils in the asthma mice model was 2.91% ± 0.76%, whereas no expression was detected in the healthy group. CD69-expressed eosinophils intrinsically have an upregulation of IL-10 mRNA expression. Moreover, CD69 crosslinking induced further pronounced IL-10 production and apoptosis; these responses were mediated via the Erk1/2 and JNK pathways, respectively. CONCLUSIONS Our results suggested that CD69+ eosinophils play an immunoregulator role in type 2 inflammation, whereas activated tissue eosinophils contribute to the pathogenesis of asthma.
Collapse
Affiliation(s)
- Dan Van Bui
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
- Allergy and Clinical Immunology Department, Hanoi Medical University, Hanoi 115000, Vietnam
- Allergy, Immunology and Dermatology Department, E Hospital, Hanoi 122000, Vietnam
| | - Linh Manh Nguyen
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Akira Kanda
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
- Laboratory Medicine Center, Kansai Medical University Hospital, Osaka 573-1010, Japan
- Allergy Center, Kansai Medical University Hospital, Osaka 573-1010, Japan
| | - Hanh Hong Chu
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
- Allergy, Immunology and Rheumatology Department, National Children Hospital, Hanoi 115000, Vietnam
| | - Nhi Kieu Thi Le
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Yasutaka Yun
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Yoshiki Kobayashi
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
- Allergy Center, Kansai Medical University Hospital, Osaka 573-1010, Japan
| | - Kensuke Suzuki
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Akitoshi Mitani
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Akihiro Shimamura
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Kenta Fukui
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| | - Shunsuke Sawada
- Dentistry and Oral Surgery and Care Center, Kansai Medical University Hospital, Osaka 573-1010, Japan;
| | - David Dombrowicz
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, 59000 Lille, France;
| | - Hiroshi Iwai
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka 573-1010, Japan (L.M.N.); (K.S.); (K.F.); (H.I.)
| |
Collapse
|
3
|
Shimizu Y, Sugimoto C, Wakao H. Potential of MAIT cells to modulate asthma. Allergol Int 2024; 73:40-47. [PMID: 37567833 DOI: 10.1016/j.alit.2023.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 07/10/2023] [Accepted: 07/19/2023] [Indexed: 08/13/2023] Open
Abstract
Despite recent advances in asthma treatments, the search for novel therapies remains necessary because there are still patients with recurrent asthma exacerbations and poor responses to the existing treatments. Since group 2 innate lymphoid cells (ILC2) play a pivotal role in asthma by triggering and exacerbating type 2 inflammation, controlling ILC2s function is key to combating severe asthma. Mucosal-associated invariant T (MAIT) cells are innate-like T cells abundant in humans and are activated both in a T cell receptor-dependent and -independent manner. MAIT cells are composed of MAIT1 and MAIT17 based on the expression of transcription factors T-bet and RORγt, respectively. MAIT cells play pivotal roles in host defense against pathogens and in tissue repair and are essential for the maintenance of immunity and hemostasis. Our recent studies revealed that MAIT cells inhibit both ILC2 proliferation and functions in a mouse model of airway inflammation. MAIT cells may alleviate airway inflammation in two ways, by promoting airway epithelial cell barrier repair and by repressing ILC2s. Therefore, reagents that promote MAIT cell-mediated suppression of ILC2 proliferation and function, or designer MAIT cells (genetically engineered to suppress ILC2s or promote repair of airway damage), may be effective therapeutic agents for severe asthma.
Collapse
Affiliation(s)
- Yasuo Shimizu
- Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, Japan; Respiratory Endoscopy Center, Dokkyo Medical University Hospital, Tochigi, Japan; Regenerative Center, Dokkyo Medical University Hospital, Tochigi, Japan.
| | - Chie Sugimoto
- Center for the Frontier Medicine, Host Defense Division, Dokkyo Medical University, Tochigi, Japan
| | - Hiroshi Wakao
- Center for the Frontier Medicine, Host Defense Division, Dokkyo Medical University, Tochigi, Japan
| |
Collapse
|